MOUNTAIN VIEW, Calif.,
June 15, 2021 /PRNewswire/ -- Aditx
Therapeutics, Inc. ("Aditxt") (NASDAQ: ADTX), a biotech innovation
company with a mission to improve the health of the immune system,
today announced that it is set to join the Russell Microcap® Index,
effective after the US market opens on June
28, 2021.
Membership in the Russell Microcap® Index, which
remains in place for one year, establishes automatic inclusion in
the appropriate growth and value style indexes. FTSE Russell
determines membership for its Russell indexes primarily by
objective, market-capitalization rankings and style attributes.
"We are pleased that Aditxt has been selected for inclusion in
the Russell Microcap® Index," said Amro
Albanna, co-founder and CEO of Aditxt. "We believe this has
the potential to broaden our shareholder base by spotlighting the
critical nature of our work in immune science and increasing our
stock's visibility with institutional investors."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.6 trillion in assets are benchmarked against
Russell's US indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
For more information on Russell Microcap® Index and the Russell
indexes reconstitution, go to the "Russell Reconstitution" section
on the FTSE Russell website.
About Aditxt:
Aditxt is developing technologies
specifically focused on improving the health of the immune system
through immune monitoring and reprogramming. Aditxt's immune
monitoring technology is designed to provide a personalized
comprehensive profile of the immune system. Aditxt's immune
reprogramming technology is currently at the pre-clinical stage and
is designed to retrain the immune system to induce tolerance with
an objective of addressing rejection of transplanted organs,
autoimmune diseases, and allergies. For more information, please
visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of federal securities laws. Forward looking statements
include statements regarding the Company's intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company's ongoing and planned product and
business development; the Company's intellectual property position;
the Company's ability to develop commercial functions; expectations
regarding product launch and revenue; the Company's results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section titled "Risk Factors" in the Company's
most recent Annual Report on Form 10-K, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company's other filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Media and Investor Relations Contact:
Sunny
Uberoi
Chief Communications Officer
Aditxt
ir@aditxt.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aditxt-set-to-join-russell-microcap-index-301312337.html
SOURCE Aditxt Therapeutics